Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05150652 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
A Phase 2 study of Breast Cancer and Breast Carcinoma, sponsored by Irada Ibrahim-zada.
- Active
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05150652 is a Phase 2 study of Breast Cancer and Breast Carcinoma that is active but no longer recruiting, run by Irada Ibrahim-zada. The registered enrollment target is 8 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05150652, a Phase 2 study of Breast Cancer and Breast Carcinoma, is active but no longer recruiting, sponsored by Irada Ibrahim-zada.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Letrozole 2.5mg
- DRUG Anastrozole 1mg
- DRUG Exemestane 25 mg
Study Locations (1)
Kentucky
- University of Kentucky Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2026-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05150652
The ClinicalTrials.gov registry entry for NCT05150652 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Irada Ibrahim-zada, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Tamoxifen is the first listed.
NCT05150652 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT05150652 about?
NCT05150652 is a clinical study titled "Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer". The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
What is the current status of trial NCT05150652?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-02-18. Estimated completion is 2026-06-09.
What conditions does trial NCT05150652 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Carcinoma, HER2-Negative Breast Cancer, Node Negative Breast Cancer.
What interventions are being tested in trial NCT05150652?
The interventions under investigation include: Tamoxifen (DRUG), Letrozole 2.5mg (DRUG), Anastrozole 1mg (DRUG), Exemestane 25 mg (DRUG).
Who is sponsoring clinical trial NCT05150652?
This trial is sponsored by Irada Ibrahim-zada, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05150652 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.